key: cord-0711252-kimyvw4w
authors: Liu, Meng-Yuan; Zheng, Bo; Zhang, Yan; Li, Jian-Ping
title: Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019
date: 2020-05-19
journal: Chronic Dis Transl Med
DOI: 10.1016/j.cdtm.2020.05.003
sha: 1255096b56821d6be4ad568b0563e6f8c85774bb
doc_id: 711252
cord_uid: kimyvw4w

Coronavirus disease 2019 is a major threat to public health globally. Though its pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has been recently identified as a receptor for the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the cell. Here, we aimed to clarify the potential role of ACE2 in SARS-CoV-2-induced acute lung injury and its underlying mechanism. As a receptor for coronavirus, ACE2 mediates the entry of SARS-CoV-2 into cells in a similar way as for severe acute respiratory syndrome coronavirus (SARS-CoV). The high binding affinity of SARS-CoV-2 to ACE2 correlates with its efficient spread among humans. On the other hand, ACE2 negatively regulates the renin-angiotensin-aldosterone system (RAAS) primarily by converting angiotensin II to angiotensin 1–7, which exerts a beneficial effect on coronavirus-induced acute lung injury. Human recombinant ACE2 has been considered as a potential therapy for SARS-CoV-2 by blocking virus entry and redressing the imbalance of RAAS in SARS-CoV-2 infection. The level of ACE2 expression can be upregulated by treatment with an ACE inhibitor (ACEI) or angiotensin Ⅱ type 1 receptor blocker (ARB). To date, no evidence shows that ACEIs or ARBs increase the susceptibility and mortality of patients infected with SARS-CoV-2, and hence, it is not advisable to discontinue such drugs in patients with cardiovascular disease.

mechanism. As a receptor for coronavirus, ACE2 mediates the entry of SARS-CoV-2 11 into cells in a similar way as for severe acute respiratory syndrome coronavirus 12 (SARS-CoV). The high binding affinity of SARS-CoV-2 to ACE2 correlates with its 13 efficient spread among humans. On the other hand, ACE2 negatively regulates the 14 renin-angiotensin-aldosterone system (RAAS) primarily by converting angiotensin II 15 to angiotensin 1-7, which exerts a beneficial effect on coronavirus-induced acute lung 16 injury. Human recombinant ACE2 has been considered as a potential therapy for 17 SARS-CoV-2 by blocking virus entry and redressing the imbalance of RAAS in 18 SARS-CoV-2 infection. The level of ACE2 expression can be upregulated by 19 treatment with an ACE inhibitor (ACEI) or angiotensin type 1 receptor blocker Ⅱ 20 (ARB). To date, no evidence shows that ACEIs or ARBs increase the susceptibility 21 and mortality of patients infected with SARS-CoV-2, and hence, it is not advisable to 22 discontinue such drugs in patients with cardiovascular disease. Angiotensin-converting enzyme 2 (ACE2), an important metalloproteinase, plays 51 a key role in SARS-CoV-2 infection. 1 ACE2 not only mediates viral infection but also 52 exerts important regulatory effects on the renin-angiotensin-aldosterone system 53 (RAAS) and participates in the development of acute lung injury (ALI) after infection. 54

Intervention measures that target ACE2 may improve the prognosis of patients with 55 COVID-19. This paper comprehensively describes ACE2 structure and function, 56 regulation of ACE2 expression, and its role in viral infection and ALI. 57 58 ACE2 overview 59 ACE2 was discovered in 2000 as a homolog of angiotensin-converting enzyme 60 (ACE). 5,6 ACE2 is a type I transmembrane protein comprised of 805 amino acids. 61 ACE2 contains two domains, the amino-terminal and the carboxy-terminal domain. 62

The amino-terminal catalytic domain contains one active site, a zinc metalloprotein 63 domain that shares 41.8% sequence identity with ACE. 5-7 The gene that encodes 64 ACE2 is located on the X-chromosome at Xp22.2. 8 ACE2 is expressed in the human 65 heart, kidneys, lungs, liver, testes, and intestines. 6 In the heart and large vessels, 66 ACE2 is localized on the surface of endothelial and smooth muscle cells. In the 67 kidneys, ACE2 is mainly expressed on the apical membrane of proximal tubular 68 epithelial cells and colocalized with ACE. 9 In the lungs, ACE2 is mainly located on 69 type II pneumocytes, or may be found on type I pneumocytes and airway epithelial 70 cells. 10 71 72

The functions of ACE2 can be broadly classified into two types: protease and 74 protease-independent functions. 75

ACE2 is a metalloproteinase and its active domain is exposed on the cell surface 77 to facilitate the catalysis of circulating polypeptides. ACE2 can cleave angiotensin I 78 into inactive angiotensin 1-9 (Ang 1-9) peptide, 5,6 which is further converted by ACE 79 or other peptidases into angiotensin 1-7 (Ang 1-7) peptide. 5 Moreover, ACE2 can 80 efficiently metabolize angiotensin (Ang ) into Ang 1 Ⅱ Ⅱ -7, which binds to Mas 81 receptor (Mas), a G-protein coupled receptor, to exert vasodilation and 82

anti-proliferation effects. 11 It is well established that Ang II has two G-protein-coupled receptors, the angiotensin type 1 receptor (AT1R) and 84 angiotensin receptor type 2 receptor (AT2R).

Ⅱ Ang II exerts its biological functions 85 and is involved in in pathogenesis of various diseases mainly through AT1R. The 86 activation of ACE/Ang II/AT1R pathway leads to vasoconstriction, proliferation, 87 fibrosis and inflammation, which may ultimately result in progressive tissue damage. 9 88

The effects of Ang 1-7 counterbalance the deleterious effects of the ACE/Ang 89 II/AT1R pathway 12-15 ( Figure 1 ). Ang 1-7 exerts multiple cardioprotective effects, 90

including anti-inflammatory, anti-thrombotic, anti-fibrotic, anti-arrhythmic, and 91 natriuretic effects. It has also been shown to inhibit cardiac hypertrophy and plaque 92 formation, and ameliorate vascular dysfunction. 16 The ACE2/Ang 1-7/Mas pathway 93 has shown beneficial effects in many animal models of hypertension, heart failure, 94 ischemic cardiomyopathy, and non-ischemic cardiomyopathy. 17 In the lungs, the Ang 95

and pro-inflammatory cytokines to alleviate lung inflammation. In addition, it also 97 improves oxygenation, reduces airway hyperresponsiveness, decreases alveolar 98 epithelial cell apoptosis, and inhibits fibroblast proliferation and migration, goblet cell 99 metaplasia, and airway remodeling. The ACE2/Ang 1-7/Mas pathway has been 100 shown to exert protective effects on the lungs in animal models of ARDS, asthma, 101 pulmonary fibrosis, and pulmonary hypertension. 18 In addition, in vitro experiments 102 have shown that ACE2 cleaves apelin-13 to remove one amino acid from the 103 C-terminal, 11 which affects the hypotensive effects of apelin-13. 104 105 106

In addition to protein cleavage, ACE2 has other important biological functions. 108 with the AT1R antagonists, losartan and olmesartan, for 28 days, the cardiomyocyte 151 ACE2 mRNA level increased by 97% and 42%, respectively. This suggested that the 152 cardioprotective effects of AT1R antagonists on myocardial infarction were partially 153 mediated by ACE2. Subsequent studies showed that myocardial ACE2 mRNA levels 154

were significantly increased when lisinopril, losartan, and a combination of these two 155 drugs were administered to rats continuously for 12 days. In addition, losartan 156 monotherapy or combined therapy with lisinopril has been shown to significantly 157 increase myocardial ACE2 activity in rats. 31 186 The whole genome sequence of SARS-CoV-2 was successfully determined by 187 next-generation sequencing 1 . A comparison with the genome sequences of previously 188 detected coronaviruses showed that SARS-CoV-2 was closely related to two bat 189

Evolutionary analysis showed that SARS-CoV-2 belonged to the subgenus 191 Sarbecovirus in the genus Betacoronavirus. A comparison of the spike protein 192 sequences between SARS-CoV-2 and SARS-CoV showed that the similarity of the 193 entire spike protein sequence was 76%-78%, RBD was 73%-76%, and receptor 194 binding motif (RBM) was 50%-53%. 37 The high sequence similarity in spike proteins 195 between these two viruses suggested that they utilized the same receptor, ACE2. 196 Further analysis showed that ACE2 not only mediated SARS-CoV-2 infection in 197

humans, but also resulted in human-to-human transmission. The RBD of 198 SARS-CoV-2 interacted with ACE2 through its polar residues. 38 virus-binding hotspots at the RBD/ACE2 interface, which increased binding interface 204 stability. Therefore, the affinity between the RBD of SARS-CoV-2 and ACE2 was 205 significantly higher than that between the RBD of SARS-CoV and ACE2. 42 The 206

higher affinity of SARS-CoV-2 for ACE2 enabled easier human-to-human 207 transmission. 43 Hoffmann et al 44 performed in vitro experiments and showed that 208 SARS-CoV-2 used host cell proteases to cleave the spike protein at the S1/S2 and S2' 209 sites, thereby activating it, and then utilized ACE2 as a receptor to enter target cells. 210

Both SARS-CoV-2 and SARS-CoV used transmembrane serine protease 2 to activate 211 their spike proteins. Unlike in SARS-CoV, a furin cleavage site has been shown to be 212 present between the S1/S2 subunits in SARS-CoV-2. 38 infected with SARS-CoV-2. In addition, ALI was shown to be less severe in complete 230

Ace knockout (Ace -/ -) mice, followed by partial Ace knockout (Ace + / -) mice, which 231 suggested that the expression level of ACE was associated with the severity of lung 232 injury. Furthermore, lung injury was found to be less severe in AT1a receptor 233 knockout mice than that in wild-type mice. 49 In another study, the expression level of 234

Ang II in mice was increased after injection of recombinant SARS spike protein, and 235 treatment with an AT1R antagonist alleviated acute respiratory distress in these 236

was associated with ARDS susceptibility and prognosis. The proportion of ARDS 238 patients with the D/D genotype was higher than that of control individuals with the 239 D/D genotype, and the mortality rate of ARDS patients with the D/D genotype was 240 higher than that of ARDS patients with the I/I genotype. 50 These results showed that 241 ACE/Ang /AT1R might mediate ALI pathogenesis.

Ⅱ 242 In an animal model of ALI induced by acid aspiration and sepsis, the 249 clinicopathological presentation of Ace2 knockout mice was worse than that of 250 wild-type mice, and the mortality rate was increased. 49 To further validate the effects 251 of ACE2 in ALI, Imai et al 49 injected recombinant human ACE2 (rhACE2) into these 252 mice. The results showed that treatment with rhACE2 significantly alleviated lung 253 injury induced by acid aspiration. This phenomenon was present in both Ace2 254 knockout and wild-type mice. However, injection of rhACE2 without catalytic 255 activity could not alleviate acid aspiration-induced ALI. These results suggest that 256 ACE2 with catalytic activity has a protective role in ALI. 257

In an acid aspiration-induced ALI model, the Ang II levels in the lungs and 258 plasma of Ace2 knockout mice were found to be significantly higher than those in 259 wild-type mice. However, treatment with rhACE2 alleviated lung injury and 260 simultaneously decreased Ang II expression, and treatment with an AT1R antagonist 261 or ACE inactivation alleviated ALI in Ace2 knockout mice. 49 These results suggested 262 that ACE2 negatively regulated ACE/Ang I /AT1R to alleviate ALI. Although there is few direct evidence of SARS-CoV-2-induced ALI, we 296 speculate that SARS-CoV-2 and SARS-CoV have a similar pathogenesis owing to 297 their high homology. An in-depth understanding of the pathogenesis of SARS-CoV-2 298 will help in the development of targeted interventions to control the COVID-19 299 epidemic. ACE2 is not only a receptor that mediates coronavirus infection, but is also 300 an important RAAS enzyme that regulates virus infection-induced ALI. Although 301 increased ACE2 expression may elevate the risk of coronavirus infection, it may also 302 have protective effects against ALI. However, the effects of enhanced ACE2 303 expression (such as RAAS inhibition) on SARS-CoV-2 susceptibility and patient 304 outcomes are not fully understood, and further basic and clinical studies are urgently 305 required. 306

Genomic characterisation and epidemiology of 2019 309 novel coronavirus: implications for virus origins and receptor binding

The reproductive number of

COVID-19 is higher compared to SARS coronavirus

Risk Factors Associated With Acute Respiratory 315

Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia 316 in Wuhan, China

Pathological findings of COVID-19 associated with 319 acute respiratory distress syndrome

A novel angiotensin-converting 321 enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin

A human 324 homolog of angiotensin-converting enzyme. Cloning and functional expression as a 325 captopril-insensitive carboxypeptidase

The angiotensin-converting enzyme gene family: 327 genomics and pharmacology

Angiotensin-converting enzyme 2 is an 329 essential regulator of heart function

Angiotensin converting enzyme 2 and the kidney

Single-cell RNA expression 333 profiling of ACE2, the putative receptor of Wuhan 2019-nCov

Hydrolysis of biological peptides by human 336 angiotensin-converting enzyme-related carboxypeptidase

Angiotensin-(1-7) is an 339 endogenous ligand for the G protein-coupled receptor Mas

ACE2 of the heart: From angiotensin 342 I to angiotensin (1-7)

ACE2: a new target for cardiovascular disease 344 therapeutics

Genetically altered animal 346 models for Mas and angiotensin

Hypertension: renin-angiotensin-aldosterone system alterations

Role of the ACE2/Angiotensin

Axis of the Renin-Angiotensin System in Heart Failure

Angiotensin-converting enzyme 2 is a 357 functional receptor for the SARS coronavirus

Structure of SARS coronavirus spike 359 receptor-binding domain complexed with receptor

Tissue-specific amino acid transporter 361 partners ACE2 and collectrin differentially interact with hartnup mutations

Characterization of renal 364 angiotensin-converting enzyme 2 in diabetic nephropathy

Increased angiotensin-(1-7)-forming 367 activity in failing human heart ventricles: evidence for upregulation of the 368 angiotensin-converting enzyme Homologue ACE2

Smoking 370

Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site 371 for Novel Coronavirus SARS-CoV-2 (Covid-19)

A crucial role of angiotensin converting enzyme 2 373 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin converting enzyme 2 375 in the kidney

Identification of target genes of 377 the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell 378 line

Role of HIF-1alpha in the regulation ACE and 380 ACE2 expression in hypoxic human pulmonary artery smooth muscle cells

Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by 384 miR-421

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by 387 blockade of angiotensin II receptors

Effect of angiotensin-converting 389 enzyme inhibition and angiotensin II receptor blockers on cardiac 390 angiotensin-converting enzyme 2

Mineralocorticoid receptor 392 blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure 393 patients

Osterhaus AD, Haagmans BL. Interferon-gamma and interleukin-4

downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells

Tissue specific up regulation of ACE2 in rabbit 398 model of atherosclerosis by atorvastatin: role of epigenetic histone modifications

SARS coronavirus entry into host cells through a 401 novel clathrin-and caveolae-independent endocytic pathway

Modulation of

TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces

TNF-alpha production and facilitates viral entry

Receptor Recognition by the Novel 408

Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of 409 SARS Coronavirus

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Functional assessment of cell entry and receptor 414 usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structural basis for the recognition 417 of SARS-CoV-2 by full-length human ACE2

Structural basis of receptor recognition by

SARS-CoV-2. Nature

Characterization of the receptor-binding domain 422 (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a 423 viral attachment inhibitor and vaccine

Cryo-EM structure of the 2019-nCoV spike 426 in the prefusion conformation

SARS-CoV-2 Cell Entry 428

Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 429

The pathogenicity of SARS-CoV-2 in hACE2 431 transgenic mice

The acute respiratory distress syndrome

Acute lung injury by sepsis and acid aspiration: 436 a key role for cytosolic phospholipase A2

Clinical and biochemical indexes from 438 2019-nCoV infected patients linked to viral loads and lung injury

Angiotensin-converting enzyme 2 protects from 441 severe acute lung failure

Angiotensin converting enzyme 443 insertion/deletion polymorphism is associated with susceptibility and outcome in 444 acute respiratory distress syndrome

stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus 447 (SARS-CoV) infection in vitro

Recombinant angiotensin-converting 449 enzyme 2 improves pulmonary blood flow and oxygenation in 450 lipopolysaccharide-induced lung injury in piglets

Susceptibility to SARS coronavirus S 452 protein-driven infection correlates with expression of angiotensin converting enzyme 453 2 and infection can be blocked by soluble receptor

Inhibition of SARS-CoV-2 infections in 456 engineered human tissues using clinical-grade soluble human ACE2

Pharmacokinetics and 459 pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in 460 healthy human subjects

A pilot clinical trial of recombinant human 462 angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Recombinant human ACE2: acing out angiotensin II in ARDS 465 therapy

Diminazene attenuates pulmonary 467 hypertension and improves angiogenic progenitor cell functions in experimental 468 models

Renin-Angiotensin-Aldosterone System 470

Blockers and the Risk of Covid-19

System Inhibitors and Risk of Covid-19

Compensation of ACE2 Function for Possible Clinical Management of 476 2019-nCoV-Induced Acute Lung Injury

None.